 | • レポートコード：B-MOR-08213 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、糖鎖生物学の世界市場について調べ、糖鎖生物学の世界規模、市場動向、市場環境、製品別（酵素、計測機器、キット、試薬）分析、用途別（診断、創薬・薬剤開発、腫瘍学、免疫学、その他）分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・糖鎖生物学の世界市場インサイト ・糖鎖生物学の世界市場環境 ・糖鎖生物学の世界市場動向 ・糖鎖生物学の世界市場規模 ・糖鎖生物学の世界市場規模：製品別（酵素、計測機器、キット、試薬） ・糖鎖生物学の世界市場規模：用途別（診断、創薬・薬剤開発、腫瘍学、免疫学、その他） ・糖鎖生物学の世界市場規模：エンドユーザー別 ・糖鎖生物学の世界市場：地域別市場規模・分析 ・糖鎖生物学の北米市場規模・予測 ・糖鎖生物学のアメリカ市場規模・予測 ・糖鎖生物学のヨーロッパ市場規模・予測 ・糖鎖生物学のアジア市場規模・予測 ・糖鎖生物学の日本市場規模・予測 ・糖鎖生物学の中国市場規模・予測 ・糖鎖生物学のインド市場規模・予測 ・糖鎖生物学の韓国市場規模・予測 ・関連企業情報・競争状況 |
The Glycobiology market is expected to register a CAGR of around 13%, during the forecast period, 2018 to 2023. Glycobiology is an important field in life sciences and involves the study of glycans that play diverse roles in study of bacterial physiology, novel drugs development, and proteomics research. Various technologies, such as mass spectrometry, MALDI-TOF, etc are used by researchers for glycomics application. Thus, the demand for glycobiology instruments, including mass spectrometers and MALDI-TOF mass spectrometry, is expected to increase in the near future.
Growing R&D Expenditure by Pharmaceutical and Biotech Companies
The major pharmaceutical and biotech companies are investing heavily into the research and development of superior biological products, such as glycobiology products and products related to proteomics. Glycobiology or complex carbohydrates can be used for a variety of physiological processes such as signal transduction to tissue development. These properties make a glycobiology an attractive option for big pharma and biotech companies to invest in. Along with this other factor, such as increasing government and private funding for glycomics and proteomics will act as drivers for the glycobiology market. Other factor, such as increasing government and private funding for glycomics and proteomics research will also help boost market growth.
High Product Cost
Huge amount of investment is put into development of products involving glycobiology. Also, the approval of drugs that are developed require lot of regulatory stages that need for process. This, in turn, renders these products very expensive. Patients and physicians may not be interested in such expensive alternatives and this in turn may become a restraining factor for the market of glycobiology. Along with this, the lack of availability of skilled professionals in the field of proteomics ad glycomics may act as a restraining factor for the growth of the market for glycobiology. Other factor, such as low availability of skilled professionals will lead to a slowdown in the growth of the glycobiology market
Maximum Growth to be witnessed by the North American Market
North America is expected to lead the global market. The easy accessibility to healthcare, affordable healthcare, and high rate of adoption about health care analytics and disorders amongst the overall population is projected to drive the regional market. The glycobiology market is also see a substantial rise as the region has a strong presence of the largest pharmaceutical companies and high demand for novel drugs and biotechnological products. In the APAC region the ever-increasing pool of geriatrics is anticipated to drive these regional markets. Asia-Pacific will grow at a considerable rate in the global market during the forecast period. The increasing expenditure on healthcare in the emerging economies is expected to be pivotal to this regional market’s growth.
Key Developments in the Market
• February 2017 – Siliq (brodalumab) a drug developed using glycobiology from Valeant Pharmaceuticals was approved by the FDA for the treatment of plaque psoriasis
• February 2017 – Rhofade (oxymetazoline hydrochloride) a drug developed using glycomicsfrom Allergan was approved by the FDA for the treatment of facial erythema associated with rosacea
Major players – AGILENT TECHNOLOGIES, BRUKER CORPORATION, DANAHER CORPORATION, MERCK KGAA, NEW ENGLAND BIOLABS, PROZYME, SHIMADZU CORPORATION, TAKARA BIO, THERMO FISHER SCIENTIFIC, WATERS CORPORATION, amongst others.
Reasons to Purchase this Report
• Current and future Glycobiology Market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
6.1.2 Growing R&D Expenditure by Pharmaceutical and Biotechnology Companies
6.2 Market Restraints
6.2.1 High Product Cost
6.2.2 Low Availability of Skilled Professionals
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Product
7.1.1 Enzymes
7.1.1.1 Glycosidases
7.1.1.2 Glycosyltransferases
7.1.1.3 Neuraminidases
7.1.1.4 Sialyltransferases
7.1.1.5 Other Enzymes
7.1.2 Instruments
7.1.2.1 Antibody Arrays
7.1.2.2 HPLC
7.1.2.3 Lectin Arrays
7.1.2.4 MALDI-TOF
7.1.2.5 Mass Spectrometers
7.1.2.6 Other
7.1.3 Kits
7.1.3.1 Glycan Labeling Kits
7.1.3.2 Glycan Purification Kits
7.1.3.3 Glycan Release Kits
7.1.3.4 Other
7.1.4 Reagents
7.1.4.1 Glycoproteins
7.1.4.2 Monosaccharides
7.1.4.3 Oligosaccharides
7.1.4.4 Other
7.2 By Application
7.2.1 Diagnostics
7.2.2 Drug Discovery & Development
7.2.3 Oncology
7.2.4 Immunology
7.2.5 Other
7.3 By End-user
7.3.1 Pharmaceutical & Biotechnology Companies
7.3.2 Contract Research Organizations
7.3.3 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Agilent Technologies
9.2 Bruker Corporation
9.3 Danaher Corporation
9.4 Merck KGaA
9.5 New England Biolabs
9.6 ProZyme
9.7 Shimadzu Corporation
9.8 Takara Bio
9.9 Thermo Fisher Scientific
9.10 Waters Corporation
9.11 List Not Exhaustive
10. Future of the Market